Lorlatinib Tablet shortage
Lorlatinib Tablet is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 24, 2026.
Pfizer is stopping the 25 mg lorlatinib 120-tablet bottle, with supply expected to run out by June 30, 2026. A 30-tablet bottle of the same 25 mg strength will keep being made, and Lorbrena (lorlatinib) in both 25 mg and 100 mg tablets remains listed from Pfizer as available.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Lorlatinib Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jun 15, 2026Currently in shortage1 of 1 product affected.
-
Jun 15, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Pfizer Inc. 📞 800-533-4535 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03) | — | — | Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation | — |
These rows are manufacturer reports to the FDA for Lorlatinib Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Lorlatinib Tablet? options further down this page.
Why is Lorlatinib Tablet in shortage?
Pfizer has let the FDA know that they are permanently stopping production of one specific package size of Lorbrena (lorlatinib) 25 mg — the larger 120-tablet bottle. They haven't shared a specific public reason for this decision. The supply of that 120-tablet bottle is expected to run out around June 30, 2026.
The good news is that the 30-tablet bottle of Lorbrena 25 mg is not going away — Pfizer says they will continue manufacturing that size. So this is about one particular bottle size being discontinued, not the 25 mg strength itself, at least from Pfizer.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Lorlatinib Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Lorlatinib Tablet?
Lorlatinib (brand name Lorbrena) tablets are currently on the FDA shortage list, so I want to walk you through what this means for you.
The affected item is the 25 mg strength sold in the 120-tablet bottle with a child-resistant closure. That specific package has no available source right now and is listed as being discontinued, with existing supply expected to run out by June 30, 2026. The important detail is that this affects only that one bottle size. The same 25 mg tablet packaged in a 30-tablet bottle is reported to continue being made, and the same medicine (Lorbrena) is also listed in a 100 mg tablet. So the medicine itself remains on the market — it is the larger bottle that is going away.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy whether they can order the same medicine in the 30-tablet bottle, or another available package, through their wholesalers — though it may not be in local stock.
- Because this bottle size is being discontinued, talk with your prescriber or pharmacist about a steady plan going forward, such as a different package or strength to make up your dose.
The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Lorlatinib Tablet?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Lorlatinib Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Lorbrena | LORLATINIB 25 mg/1 | Tablet, Film Coated · Oral | Pfizer Laboratories Div Pfizer Inc | 00069-0227-01 |
| Lorbrena | LORLATINIB 100 mg/1 | Tablet, Film Coated · Oral | Pfizer Laboratories Div Pfizer Inc | 00069-0231-01 |
Therapeutic equivalents & pricing 2 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Lorbrena 25 mg | Pfizer | 120 tablets | — | — | FDA listed |
| Lorbrena 25 mg | U.S. | 30 tablets | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Lorlatinib Tablet — that fall in the same broad treatment class (antineoplastic systemic enzyme inhibitors) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other oncology shortages
Lorlatinib Tablet shortage FAQs
Is Lorlatinib Tablet in shortage?
Which products are affected?
When will Lorlatinib Tablet be available again?
Can I still get Lorlatinib somewhere?
What should I do if I take Lorlatinib Tablet?
Still have a question about the Lorlatinib Tablet shortage?
Ask a pharmacist about this shortage →View Lorlatinib Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.